Treatment of ursodeoxycholic acid with glucocorticoids and immunosuppressants may improve the long-term survival rate in primary biliary cholangitis patients

Primary biliary cholangitis (PBC) is an autoimmune cholestatic liver disease. The clinical effectiveness of ursodeoxycholic acid (UDCA) plus glucocorticoids and/or immunosuppressants remains controversial in PBC patients. The study aimed to compare the efficacy of monotherapy and combination therapy in patients with PBC and to assess the factors affecting the efficacy. In this retrospective study, 266 patients diagnosed with PBC were divided into monotherapy group (UDCA), double therapy group (UDCA plus glucocorticoids or immunosuppressants), and triple therapy group (UDCA plus glucocorticoids and immunosuppressants) according to different treatments. Demographic characteristics, immune parameters, biochemistry profiles, and other indicators were evaluated at baseline, 6 months, and 1 year following treatment. The prognosis was evaluated using the Paris II standard. The liver transplant-free survival at 3, 5, 10, and 15 years was predicted by GLOBE score. All statistical analyses were conducted using SPSS (version 24) software (SPSS Inc, Chicago, IL). The long-term survival rate of the triple therapy group was significantly improved compared with the monotherapy group (P = .005). In addition, multivariate analysis showed that abnormal platelet count, alkaline phosphatase, and albumin levels were risk factors for poor response. When IgG levels were elevated but below twice the upper limit of normal, the clinical benefit was not significant compared with monotherapy (P > .05). Compared with monotherapy and double therapy, triple therapy may improve the long-term survival rate of PBC patients. Abnormal platelet count, alkaline phosphatase, and albumin levels were associated with a poor prognosis.

[1]  M. Manns,et al.  A placebo-controlled randomised trial of budesonide for primary biliary cholangitis following an insufficient response to UDCA. , 2020, Journal of hepatology.

[2]  H. Yoshiji,et al.  Bezafibrate Improves GLOBE and UK‐PBC Scores and Long‐Term Outcomes in Patients With Primary Biliary Cholangitis , 2019, Hepatology.

[3]  G. Hirschfield,et al.  The Pathogenesis of Primary Biliary Cholangitis: A Comprehensive Review , 2019, Seminars in Liver Disease.

[4]  B. Feng,et al.  [Situation analysis of timing of first visit of anti-mitochondrial antibody-positive patients]. , 2019, Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology.

[5]  F. Nevens,et al.  Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis. , 2019, Journal of hepatology.

[6]  J. Boyer,et al.  Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases , 2018, Hepatology.

[7]  A. Parés.  Primary biliary cholangitis. , 2018, Medicina clinica.

[8]  C. Levy,et al.  Cholestatic liver diseases: new targets, new therapies , 2018, Therapeutic advances in gastroenterology.

[9]  U. Beuers,et al.  Role of Bile Acids and the Biliary HCO3- Umbrella in the Pathogenesis of Primary Biliary Cholangitis. , 2018, Clinics in liver disease.

[10]  A. Lohse,et al.  Variant syndromes of primary biliary cholangitis. , 2018, Best practice & research. Clinical gastroenterology.

[11]  R. Chapman,et al.  A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis , 2018, Hepatology.

[12]  K. Lindor,et al.  Increasing Prevalence of Primary Biliary Cholangitis and Reduced Mortality With Treatment , 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[13]  G. Hirschfield,et al.  EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. , 2017, Journal of hepatology.

[14]  Jagpreet Chhatwal,et al.  Long‐term clinical impact and cost‐effectiveness of obeticholic acid for the treatment of primary biliary cholangitis , 2017, Hepatology.

[15]  J. Fang,et al.  The risk predictive values of UK‐PBC and GLOBE scoring system in Chinese patients with primary biliary cholangitis: the additional effect of anti‐gp210 , 2017, Alimentary pharmacology & therapeutics.

[16]  W. Cai,et al.  Glucocorticoid treatment alters systemic bile acid homeostasis by regulating the biosynthesis and transport of bile salts. , 2016, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[17]  A. Burroughs,et al.  University of Birmingham Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy , 2022 .

[18]  A. Floreani,et al.  Extrahepatic Autoimmune Conditions Associated with Primary Biliary Cirrhosis , 2015, Clinical Reviews in Allergy & Immunology.

[19]  M. Trauner,et al.  New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond. , 2015, Journal of hepatology.

[20]  I. Kema,et al.  Prednisolone increases enterohepatic cycling of bile acids by induction of Asbt and promotes reverse cholesterol transport. , 2014, Journal of hepatology.

[21]  G. Alexander,et al.  Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid. , 2013, Gastroenterology.

[22]  O. Chazouilleres,et al.  Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome. , 2011, Journal of hepatology.

[23]  H. Stunnenberg,et al.  Coactivation of GR and NFKB alters the repertoire of their binding sites and target genes. , 2011, Genome research.

[24]  M. Manns,et al.  Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue. , 2011, Journal of hepatology.

[25]  R. Poupon.  Primary biliary cirrhosis: a 2010 update. , 2010, Journal of hepatology.

[26]  M. Färkkilä,et al.  Pharmacokinetics and bone effects of budesonide in primary biliary cirrhosis , 2006, Alimentary pharmacology & therapeutics.

[27]  M. Färkkilä,et al.  Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: A three‐year randomized trial , 2005, Hepatology.

[28]  O. Chazouilleres,et al.  Primary biliary cirrhosis–autoimmune hepatitis overlap syndrome: Clinical features and response to therapy , 1998, Hepatology.

[29]  M. Dumont,et al.  European Association for the Study of the Liver , 1971 .